Rare Antibodies May Be Linked To AstraZeneca Covid Vaccine C
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
New research has identified unusual antibodies that appear to have caused, in rare cases, serious and sometimes fatal blood clots in people who received the AstraZeneca Covid vaccine. Exactly why the rare reactions to the vaccine occurred is still a mystery.

People who developed the clots after vaccination produced antibodies that activated platelets. Younger people appear more susceptible than older ones, researchers say. No pre-existing health conditions are known to predispose people to the rare reaction. There is no way to tell who is at high risk, they say.

Study: It's a "likely possibility" that some people who developed clotting disorder had some rare biological traits. Those traits may have led their immune systems to make powerful, misdirected antibodies. "We have no way to predict who will develop these antibodies," the study's author says.

Six of the 11 people part of the study, including nine women ages 22 to 49, died. Nine had cerebral venous thrombosis, a clot blocking a vein that drains blood from the brain. Most of the patients were female, but it is not known whether they are more vulnerable. The researchers suggested treatment with a blood product called intravenous immune globulin.

The second report, from Norway, described five patients, one male and four female health workers. All had clots and bleeding from seven to 10 days after the Astra jab. Four had severe clots in the brain, and three died. The researchers said the disorder was rare, but "a new phenomenon with devastating effects."